A path toward clinical trial diversity
Minority and marginalized communities have historically been underrepresented in local and federal governments and in dozens of private sectors globally. Pharma is no different; there exists a steep chasm that drugmakers have yet to bridge concerning research and trials. The longer this gulf exists, the harder it becomes to address – the feelings of mistrust, resentment, and disenfranchisement only get harder to overcome with time.
Over the last decade, the pharmaceutical …
A path toward clinical trial diversity






![Clinicians are failing at value-based care because no one taught them the system [PODCAST]](https://kevinmd.com/wp-content/uploads/bd31ce43-6fb7-4665-a30e-ee0a6b592f4c-190x100.jpeg)













![Silence at the chessboard changed how I talk to patients [PODCAST]](https://kevinmd.com/wp-content/uploads/b664dfaa-d79f-41b8-9445-d43d50340ea4-190x100.png)